Kindred Biosciences (Kindred Biosciences) Total Liabilities : $29.10 Mil (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences Total Liabilities?

Kindred Biosciences's Total Liabilities for the quarter that ended in Jun. 2021 was $29.10 Mil.

Kindred Biosciences's quarterly Total Liabilities declined from Dec. 2020 ($28.33 Mil) to Mar. 2021 ($26.19 Mil) but then increased from Mar. 2021 ($26.19 Mil) to Jun. 2021 ($29.10 Mil).

Kindred Biosciences's annual Total Liabilities increased from Dec. 2018 ($15.28 Mil) to Dec. 2019 ($32.10 Mil) but then declined from Dec. 2019 ($32.10 Mil) to Dec. 2020 ($28.33 Mil).

Kindred Biosciences Total Liabilities Historical Data

The historical data trend for Kindred Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindred Biosciences Total Liabilities Chart

Kindred Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Liabilities

Get a 7-Day Free Trial

3.90

6.14

15.28

32.10

28.33

Kindred Biosciences Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Total Liabilities	Get a 7-Day Free Trial															29.13	28.00	28.33	26.19	29.10

Kindred Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kindred Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.896	+	(21.436	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	28.33

Total Liabilities	=	Total Assets (A: Dec. 2020 )	-	Total Equity (A: Dec. 2020 )
	=	95.814	-	67.482
	=	28.33

Kindred Biosciences's Total Liabilities for the quarter that ended in Jun. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.26	+	(17.843	+	3.5527136788005E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	29.10

Total Liabilities	=	Total Assets (Q: Jun. 2021 )	-	Total Equity (Q: Jun. 2021 )
	=	108.872	-	79.769
	=	29.10

Kindred Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindred Biosciences (Kindred Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010

Website

https://www.kindredbio.com

Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.

Executives

Richard Chin	director, officer: Chief Executive Officer	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee	officer: Chief Financial Officer	C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken	director	C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery	director	C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi	director	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof	officer: SVP of Regulatory Affairs	C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley	officer: Chief Commercial Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker	officer: Chief Financial Officer	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz	officer: Chief Scientific Officer	C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010